BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.
The National Comprehensive Cancer Network (NCCN) guidelines on breast cancer now allow physicians to pinpoint the women who are most likely to benefit from post-mastectomy radiation using the latest targeted testing techniques.
The FDA has approved osimertinib (Tagrisso) for frontline use in patients with non–small cell lung cancer (NSCLC) who have EGFR-mutated tumors.
The FDA has granted priority review to a supplemental biologics license application for nivolumab (Opdivo) to be used to treat patients with small cell lung cancer who have already had two or more lines of therapy, and whose disease has continued to progress.
Significant improvements over chemotherapy alone makes frontline pembrolizumab (Keytruda) treatment a clear choice.
The FDA approved fostamatinib disodium hexahydrate (Tavalisse), an SYK inhibitor, as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.
Findings from a phase III randomized clinical trial offer new hope to some patients who have advanced myelofibrosis.
Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic castration-resistant prostate cancer.
The FDA has approved the combination of immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) as a frontline treatment for patients with advanced renal cell carcinoma (RCC).
To address the shortage of common IV fluids, many healthcare facilities are now rationing IV fluids and prioritizing their use.
Systematic exposure to bright morning light could help patients with cancer and survivors sleep better and experience less fatigue.
Two congressmen, who are also cancer survivors, proposed the Cancer Care Planning and Communications (CCPC) Act, which would create a Medicare billing code that would reimburse providers for their time and resources used to create survivorship care plans for patients with Medicare.
The American Society for Radiation Oncology released an updated guideline which states that some patients with incurable non-small cell lung cancer should receive concurrent chemotherapy along with palliative thoracic radiation therapy.
The surgical landscape for non-small cell lung cancer is shifting now that durvalumab (Imfinzi), the first immunotherapy for stage III NSCLC, has been approved for the FDA.
The Pivot Nurse in Oncology (PNO) role appears to make a substantial difference in care for patients being treated for advanced lung cancer, according to a study presented at the European Lung Cancer Congress (ELCC) 2018.
The FDA has granted a priority review to duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.
The American Society of Clinical Oncology released guidelines on management of immune-related adverse effects in patients treated with immune checkpoint inhibitor therapy.
The FDA has granted a priority review designation to dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to Pfizer, the manufacturer of the pan-human EGFR tyrosine kinase inhibitor (TKI).
The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.
The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia (HCL) who have received at least 2 prior lines of therapy, according to AstraZeneca (MedImmune), the developer of the anti-CD22 recombinant immunotoxin.
Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival (DFS) and overall survival (OS), according to results from the CALGB 8903 study published in the Journal of Clinical Oncology.
The combination of eflornithine (alphadifluoromethylornithine) and lomustine is currently being explored as a treatment for patients with recurrent anaplastic astrocytoma (AA).
From diagnosis to post-treatment, survivors should have access to resources that help them navigate through their cancer journey.
New research indicates that both a dependence on glycolysis and prior chemotherapy appear to reduce the potential for T cells to develop into chimeric antigen receptor (CAR) T-cell therapy.
Behavioral counseling interventions are of moderate benefit in increasing sun protection behaviors in children, adolescents, and young adults with fair skin types.
What are some things we can do to steer our patients away from bad information?
Despite initial thoughts that patients would be dissatisfied, a new “ultra-restrictive” opioid prescription protocol for gynecologic surgery led to an 89% reduction in the number of opioid tablets dispensed and a high rate of patient satisfaction.
A filgrastim (Neupogen) biosimilar, EP2006, recently produced safety results equivalent to those observed with referent filgrastim in a combined analysis of 2 phase III breast cancer studies from the United States and Europe.
The FDA has granted blinatumomab (Blincyto) an accelerated approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD).
The FDA has granted a breakthrough therapy designation to enfortumab vedotin to treat patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint therapy.
